Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GBP3 CRISPR/Cas9 KO Plasmid (h): sc-402792
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GBP3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GBP3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GBP3 CRISPR/Cas9 KO Plasmid (h) | sc-402792 | 20 µg | $397.00 |
Overview
Guanylate binding protein 3 (GBP3) is a human interferon-inducible large GTPase that participates in innate immune defense programs downstream of type I/II interferon signaling. GBP3 contributes to cell-intrinsic antimicrobial and antiviral responses by coordinating interferon-stimulated gene networks and regulating pathogen-restrictive and inflammatory processes, including crosstalk with inflammasome-associated pathways. Altered GBP3 expression patterns have been associated with immune dysregulation and inflammatory states, and it is frequently studied in the context of infection biology and tumor-immune interactions. As a marker and mediator of interferon-driven signaling, GBP3 is relevant for dissecting cytokine responses, host–pathogen interactions, and immune-related transcriptional programs.
GBP3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GBP3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GBP3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GBP3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GBP3 protein expression.
This CRISPR knockout system enables efficient generation of GBP3-deficient cell models for investigation of GBP3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GBP3 exon(s) critical for GBP3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GBP3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GBP3 CRISPR/Cas9 KO Plasmid (h) and GBP3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GBP3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GBP3 HDR Plasmid (h) and GBP3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GBP3 homology arms to support homology-directed repair at defined GBP3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.